Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants
Systemic sclerosis (scleroderma: SSc) is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal organ failure, and death. One of t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/521958 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556532530675712 |
|---|---|
| author | Audrey Dooley K. Richard Bruckdorfer David J. Abraham |
| author_facet | Audrey Dooley K. Richard Bruckdorfer David J. Abraham |
| author_sort | Audrey Dooley |
| collection | DOAJ |
| description | Systemic sclerosis (scleroderma: SSc) is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal organ failure, and death. One of the most important and early modulators of disease activity is thought to be oxidative stress. Evidence suggests that the free radical nitric oxide (NO), a key mediator of oxidative stress, can profoundly influence the early microvasculopathy, and possibly the ensuing fibrogenic response. Animal models and human studies have also identified dietary antioxidants, such as epigallocatechin-3-gallate (EGCG), to function as a protective system against oxidative stress and fibrosis. Hence, targeting EGCG may prove a possible candidate for therapeutic treatment aimed at reducing both oxidant stress and the fibrotic effects associated with SSc. |
| format | Article |
| id | doaj-art-110002dd6fa945809a4dfa1175279a22 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-110002dd6fa945809a4dfa1175279a222025-02-03T05:45:08ZengWileyCardiology Research and Practice2090-80162090-05972012-01-01201210.1155/2012/521958521958Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and AntioxidantsAudrey Dooley0K. Richard Bruckdorfer1David J. Abraham2Centre for Rheumatology and Connective Tissue Disease, University College London Medical School, Royal Free Campus, London NW3 2PF, UKInstitute of Structural and Molecular Biology, University College London Medical School, Gower Street, London WC1E 6BT, UKCentre for Rheumatology and Connective Tissue Disease, University College London Medical School, Royal Free Campus, London NW3 2PF, UKSystemic sclerosis (scleroderma: SSc) is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal organ failure, and death. One of the most important and early modulators of disease activity is thought to be oxidative stress. Evidence suggests that the free radical nitric oxide (NO), a key mediator of oxidative stress, can profoundly influence the early microvasculopathy, and possibly the ensuing fibrogenic response. Animal models and human studies have also identified dietary antioxidants, such as epigallocatechin-3-gallate (EGCG), to function as a protective system against oxidative stress and fibrosis. Hence, targeting EGCG may prove a possible candidate for therapeutic treatment aimed at reducing both oxidant stress and the fibrotic effects associated with SSc.http://dx.doi.org/10.1155/2012/521958 |
| spellingShingle | Audrey Dooley K. Richard Bruckdorfer David J. Abraham Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants Cardiology Research and Practice |
| title | Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants |
| title_full | Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants |
| title_fullStr | Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants |
| title_full_unstemmed | Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants |
| title_short | Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants |
| title_sort | modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants |
| url | http://dx.doi.org/10.1155/2012/521958 |
| work_keys_str_mv | AT audreydooley modulationoffibrosisinsystemicsclerosisbynitricoxideandantioxidants AT krichardbruckdorfer modulationoffibrosisinsystemicsclerosisbynitricoxideandantioxidants AT davidjabraham modulationoffibrosisinsystemicsclerosisbynitricoxideandantioxidants |